Palantir's U.K. NHS Contract Faces Political Scrutiny
Palantir Technologies (PLTR) is facing political scrutiny over its £330 million ($447 million) contract with the UK’s National Health Service to manage a data platform, raising concerns about how expansion into foreign governments might be affected by local resistance. The deal, awarded in 2023 and set for an initial three-year term expiring February 15, 2027, is under review by British authorities amid calls from lawmakers and activists to trigger termination clauses due to privacy and data sovereignty concerns. Despite the controversy surrounding its U.K. contract, Palantir’s financial performance remains strong in the United States. In Q2 2026, it reported $809 million in government revenue (up 90% year-over-year) and $764 million from commercial clients (149% growth), with total revenue reaching $1.94 billion—a 93% increase. The company also secured a record $2.13 billion in U.S. commercial contract value, highlighting its continued reliance on domestic government contracts for growth. The outcome of the NHS review could serve as an important test case for Palantir’s ability to expand into international markets and replicate its success with foreign governments.
Tickers: $PLTR
Topics: international expansion NHS contract Palantir U.S. government business